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Abstract Plasmodium falciparum (P. falciparum) malaria
presents serious public health problems worldwide. The
parasites resistance to antimalarial drugs has proven to be
a significant hurdle in the search for effective treatments
against the disease. For this reason, the study of natural
products to find new antimalarials remains a crucial step in
the fight against malaria. In this study, we aimed to study
the in vivo performance of the decoction of C. nucifera
leaves in P. berghei-infected mice. We analyzed the
effectiveness of different routes of administration and the
acute toxicity of the extract. Additionally, we determined
the suppressive, curative and prophylactic activity of the
extract. The results showed that the decoction of leaves of
C. nucifera is most effective when administered intra-
muscularly to mice in comparison to intraperitoneal, sub-
cutaneous and intragastric methods. We also found that
organ signs of acute toxicity appear at 2000 mg/kg/day as
evidenced by necropsy examination. Additionally, we
found that the prophylactic effect of the extract is of 48%
inhibition, however, there is no curative effect. Finally, in a
4-day suppressive assay, we found that the extract can
inhibit the growth of the parasite by up to 54% at sub-toxic
doses when administered intramuscularly.
Keywords Plasmodium falciparum  Cocos nucifera 
Aqueous extract  Antiplasmodial  Plasmodium berghei
Introduction
The most dangerous form of malaria is caused by Plas-
modium falciparum (P. falciparum) parasites which pre-
sent serious health problems worldwide. For the year 2017,
there were approximately 219 million cases of malaria
worldwide, compared to 217 million cases in the previous
year. There were approximately 435,000 deaths from
malaria globally in 2017, compared to 451,000 estimated
deaths in 2016. The highest disease burden is centered in
Sub-Saharan Africa, with children less than 5 years of age
being the most affected group (WHO 2018). To date, the
most effective ways to control these parasitic illnesses have
been the use of drugs to treat the diseases and insecticides
to control their transmission. Resistance to chloroquine,
and lately to artemisinin derivatives and insecticides, gives
fresh impetus to the search for new agents (Achan et al.
2018).
This search has led scientists to examine microorgan-
isms, animal fur and plants (Higginbotham et al. 2014;
Martı´nez-Luis et al. 2012; Durant et al. 2014: Isaka et al.
2018; Schorderet Weber et al. 2019; Whitman et al. 2019)
for signs of activity against various diseases. In Panama we
can find one of the planet’s most uniquely biodiverse
environments, rich in plant and animal species potentially
useful for alternative medicine studies. As part of their
conservation efforts, The National Association for the
Conservation of Nature (ANCON) protects a private nat-
ural reserve in Punta Patin˜o, Darie´n. This area is
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characterized by large extensions of coconut palm planta-
tions of Cocos nucifera (C. nucifera).
The coconut tree has traditionally been used to treat
several human diseases such as arthritis and asthma; and
symptoms such as diarrhea and fevers; as a diuretic, and to
treat malaria, among others (Lima et al. 2015). Several
studies have described the traditional use of C. nucifera
husk, water and inflorescence on mice and rats to address
several pathologies (Naskar et al. 2011; Rinaldi et al. 2009;
Renjith et al. 2013; Alviano et al. 2004; Omoboyowa et al.
2016). One study describes the use of C. nucifera leaf
extracts as reducing amyloid-b(1-42) aggregation in trans-
genic Caenorhabditis elegans (Manalo et al. 2017).
Another study describes the safety of C. nucifera leaf
extracts in mice, however, it does not evaluate the effec-
tiveness of these extracts on any pathology (Paul et al.
2012). Because we have previously reported the in vitro
antiplasmodial activity of the water extract of leaves
(Tayler et al. 2019), and because to our knowledge there
are no rigorous studies which describe the use of the leaves
of C. nucifera against P. falciparum, we decided to test its
in vivo potential as an antimalarial.
Our work focused on evaluating the inoculation route,
acute toxicity, hematological parameters and antiplas-
modial activity exerted by the aqueous extract of C. nuci-
fera leaves from the Punta Patin˜o Private Natural Reserve
in mice infected with Plasmodium berghei parasites.
Materials and methods
Ethics statement
All experimental procedures were performed in accordance
with the institutional guidelines from the Institutional
Committee of Animal Use and Care (Comite´ Institucional
de Cuidado y Uso de Animales-CICUA) under approval
number CICUA-17-004.
The authors were permitted to collect C. nucifera sam-
ples by the owners of the reserve, the National Association
for the Conservation of Nature (ANCON), a non-govern-
ment organization and stakeholder of this study. No other
permission was required for research purposes and the field
studies did not involve any endangered species.
Plant material
Leaves of C. nucifera were collected from the Punta Patin˜o
Natural Reserve in Darien, Panama. They were identified
by a botanist and voucher samples of the leaves were
deposited at the Herbarium of the Universidad de Panama
with registry number 0111279. The extracts were prepared
as described in previous work by Tayler et al. (Tayler et al.
2019). In brief, 15 g of leaves were cleansed using distilled
water and delicate task wipes (KimwipesTM, Thermo
Fisher Scientific, Waltham, MA, USA). After drying,
leaves were cut into smaller pieces and macerated with a
mortar and pistil. The leaves were placed into a sterile
beaker, covered with 250 mL of distilled water, and boiled
for 15 min. Afterwards, leaves were subsequently filtered
through sterile 0.8 lm and 0.22 lm membranes (Nalgene
vacuum filtration system). To prepare the experimental
samples, 250 lL of the extract were aliquoted into glass
vials and concentrated to reach approximately 292 mg/mL.
Samples were aliquoted and stored at 4 C until use. As
positive control in all tests, chloroquine (10 mg/Kg/day)
was applied subcutaneously.
Mice and parasites
The tests used throughout these studies were carried out on
female mice of the inbred line C57BL/6, of 7 weeks of age
with average weights of 21.5 ± 0.5 g, produced and
maintained in the animal facility of INDICASAT AIP at a
temperature of 20 C, with light cycles of 12 h light/12 h
darkness. Mice were maintained under biological barrier
conditions such as change of personal wardrobe, use of
masks and gloves and sterilization of the bedding chips and
food (121 C/15 min). Mice were handled according to the
regulations on the use of laboratory animals of INDICA-
SAT AIP. The parasites used to produce the infection were
P. berghei ANKA (chloroquine sensitive) which were
maintained in mice by successive C57BL/6 mouse - mouse
passages.
Determination of route of administration
Female mice of the consanguineous line C57BL/6 were
inoculated through intraperitoneal injection with 200 ll of
P. berghei parasites. Four days after inoculation, infected
blood was extracted through cardiac puncture and used to
inoculate test subjects. A total of 10 mice were divided into
5 groups of two mice each, which were identified by per-
manent tattooing. These groups were characterized as:
intramuscular (IM) administration, subcutaneous adminis-
tration (SC), intragastrical (IG) administration, untreated
group (control) and a chloroquine treated group injected
subcutaneously with a 10 mg/kg dose (positive control)
(Sigma, St. Louis, Missouri, USA). Mice were inoculated
intraperitoneally with approximately 1 9 107 of P. berghei
parasites (Alger 2001) and treatment started 24 h later. The
extract was administered at a dose of 100 mg/kg/day to
each group using a 1 cc syringe (Nipro Medical Corpora-
tion, Bridgewater, NJ, USA) with a puncture at the
respective site (IM and SC). Intragastric administration was
performed using an oral gavage needle. The parasitemia
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was monitored until no more parasites were observed in the
chloroquine group. To examine the parasitemia, a cut of
approximately 1 mm was made on the tail of each mouse
and blood smears were obtained which were subsequently
stained with Giemsa 1:10, and parasites counted under a
light microscope (brand OLYMPUS model BH2), with an
objective of 1009.
Toxicity assays
For the toxicity analysis, the OECD guideline on its acute
toxic class method section for the testing of chemicals was
followed (OECD 2002). After testing the suggested
2000 mg/kg/day dose, lower doses of 1000 and 750 mg/
kg/day were also analyzed. Three experimental groups of 5
mice each were formed, with each of the concentrations
above. A control group was treated with only the vehicle,
which was sterile water. The chloroquine control group
was treated with 10 mg/kg/day of drug. Another control
group was that of untreated mice. The extract was
administered via IM for 4 days for each of the concentra-
tions. Animals were observed for gross signs of toxicity
(lacrimation, hair erection and reduction in their motor and
feeding activities) 4 h after the administration of the
extract, then daily for 16 days to assess safety of the
extract. All animals were retro-orbitally sampled for
hemoglobin, hematocrit, mean corpuscular volume and
white cell counts in three moments: prior to administration
of the extract, 8 and 16 days after administration. The
blood work was performed by the Laboratory of the School
of Veterinary Science, University of Panama, Panama.
Results are average values per groups (controls and treated)
for each dose at day 1 (beginning of treatment), day 8 and
day 16 (end of the experiment). The mice were weighed
daily for 8 days and one final time 16 days after adminis-
tration of the extract. At this point, the animals were sac-
rificed by overdose of the ketamine/xylazine anesthetic
mixture (normal dose: 50-150/5-15 mg/kg body weight).
4-Day suppressive test
For the suppressive test, we followed the protocol by Al-
Adhroey et al. (2011) with some modifications. This
experiment was conducted on different days for each
concentration, wherein each experimental group had sep-
arate control groups. For this, six groups of five (5) mice
each were formed, of which two were the experimental
groups: 500 and 750 mg/kg/day. Four groups formed the
control groups, of which two were the chloroquine-treated
mice and two were the negative control mice to which only
the vehicle, sterile water, was added IM. Mice were inoc-
ulated intraperitoneally with about 1 9 107 P. berghei
parasites and, 4 h post infection, treatment was started via
IM and continued once a day for the next 4 days. Mean
survival time (days) was evaluated over a 16-day period.
Blood smears were obtained which were subsequently
stained with Giemsa 1:10 and the number of parasites was
counted under a light microscope (OLYMPUS model
BH2), with an objective of 1009.
Curative test
For the curative test, we followed the protocol by Al-
Adhroey et al. (2011) with some modifications. Five
groups of five mice each were formed; two groups were
experimental, with 500 and 750 mg/kg/day of the extract
and three control groups: one with only the vehicle
(sterile water) all injected intramuscularly, one untreated
and a group treated with subcutaneous chloroquine. Mice
were inoculated with approximately 1 9 107 P. berghei
parasites and 72 h post infection, treatment was started
(D1) via IM and continued for an additional 5 days (D5).
Blood smears were obtained daily, stained with Giemsa
1:10 and infected parasites were counted under a light
microscope, with an objective of 1009. The antimalarial
activities of the extract were compared to both control
groups treated with only the vehicle and the reference
groups treated with the standard drug (chloroquine).
Mean survival time (days) was evaluated over a 16-day
period.
Prophylactic test
Again, following basically the protocol of Al-Adhroey
et al. (2011), five groups of five mice each were formed;
two groups were experimental, with 500 and 750 mg/
kg/day of the extract and three control groups, one with
only the vehicle, another of untreated animals and a
chloroquine-treated group. All mice were given the extract
IM for 72 h. On day 1 (D1), animals were inoculated with
approximately 1 9 107 P. berghei parasites intraperi-
toneally and the treatment with the extract was continued
for an additional 3 days (4 days total). The antimalarial
activities of the extract were compared to control groups
treated with only sterile water. Parasitemia was analyzed
using Hoechst 33342 staining and flow cytometry analysis
gated on the region of erythrocyte population as explained
in another section below.
For all assays, chemosuppression was calculated with
the following formula (Angeles et al. 2005):
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Supression¼
UntreatedgroupmeanparasitemiaTreatedgroupmeanparasitemia
Untreatedmeanparasitemia
 
 100
Quantification of parasitemia using flow cytometry
Parasitemia was obtained as described in Tayler et al.
(2019). Briefly, blood samples were treated with Hoechst
33342 (Invitrogen, USA) at 2 lg/mL and incubated for
30 min while protected from light. Additionally, back-
ground staining of an uninfected red blood sample was
always performed (Spadafora et al. 2010) and used to
define the population of red blood cells using FSC/SSC to
be gated for all samples. Debris and other stained cellular
populations were ungated. Acquisition was performed with
a UV laser on a PARTEC CyFlow Space cytometer
(Go¨rlitz, Germany).
Statistics
All data was analyzed using the software GraphPad (Prism,
California, USA), performing analyses of variance. Sig-
nificant differences between groups were determined using
Bonferroni’s test. A p B 0.05 was considered significant.
Results
Determination of route of administration
The results of testing different routes of administration of
the extract determined that the most effective route was
intramuscular (IM), since even though the weight of the
mice decreased for all of the different treatments, the mice
treated intramuscularly with the extract were the ones
whose weight decreased the least (- 0.7 g), as shown in
Fig. 1. With respect to parasitemia, mice given extracts via
IM also had the lowest percentage of parasitemia (1.35%)
at day 7, of all the extract-treated groups (Table 1).
Toxicity assays
In the group of mice given the concentration of 2000 mg/
kg/day, 2 of the 5 mice died; which prompted the testing of
two other lower dosages for acute toxicity (1000 and
750 mg/kg/day). In these other two groups no mice died
and they survived until day 16 on which euthanasia was
performed. In relation to weight, it was observed that no
significant weight was lost relative to the controls at any of
the three concentrations tested. With regard to the blood
parameters, mice given the extract at 2000 mg/kg of
weight had lower hematocrit and hemoglobin values than
controls throughout the experiment. Mice given the extract
at 1000 and 750 mg/kg of weight had normal values until
the 8th day of treatment; however, all values for hematocrit
and hemoglobin were lower than controls at day 16. All
mice challenged with every concentration tested had values
within the normal range of mean corpuscular volume,
except for those treated with 750 mg/kg/day on Day 16
(VCM) (Table 2).
4-Day suppressive test
For the trials related to the 4-day suppressive test, treat-
ments with 500 and 750 mg/kg/day of the extract were
analyzed. The mean parasitemia on day 4 after infection
was 11.8% ± 8.5 for 500 mg/kg/day and 7.4% ± 4.5 for
750 mg/kg/day. The range value for the control was
24.0 ± 1.2 to 16.1 ± 2.0. The percentage chemosuppres-
sion of the parasites was 51% for 500 mg/kg/day and 54%
for 750 mg/kg/day. The daily suppressive effect can be
observed in Fig. 2. Moreover, the mice infected with P.
berghei parasites exhibited no signs of distress, such as
weight loss, diminished exploratory behavior, hunched
posture or unresponsiveness during the full length of the
assay.
Curative test
The parasitemia percentage on day 5 in mice infected and
treated with 500 and 750 mg/kg/day was 42.80 ± 4.10 and
38.73 ± 7.46, respectively, while the untreated group had
a percentage parasitemia of 39.08 ± 6.65, and that of the
chloroquine-treated group was 1.64 ± 0.23. From the point
of view of chemosuppression of the parasites, the mice
treated with 500 and 750 mg/kg/day presented an inhibi-
tion of - 9.51% and 0.91%, whereas those treated with
chloroquine had 95.81% (Fig. 3).
Fig. 1 Weight of P. berghei infected mice by different inoculation
routes. The graph represents the mean of two mice in each of the
groups. IM, intramuscular; SC, subcutaneous; IG, intragastric; CQ,
Chloroquine and control (untreated)
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Table 1 Parasitemia of Plasmodium berghei infected mice according to route of administration
Inoculation routes
Days IM SC IG CQ UT
1 0.10 ± 0.00 0.47 ± 0.0 0.40 ± 0.00 0.47 ± 0.0 0.60 ± 0.00
2 0.10 ± 0.07 1.67 ± 0.85 1.6 ± 0.85 0.03 ± 0.31 2.29 ± 1.20
3 0.00 ± 0.00 7.30 ± 3.98 8.6 ± 4.95 0.10 ± 0.05 9.80 ± 5.31
4 0.10 ± 0.07 8.95 ± 1.17 9.3 ± 0.49 0.10 ± 0.00 12.00 ± 1.56
5 0.10 ± 0.00 4.54 ± 3.12 16.00 ± 4.74 0.00 ± 0.07 15.00 ± 2.12
6 0.80 ± 0.49 6.10 ± 1.10 22.00 ± 4.24 0.00 ± 0.00 21.00 ± 4.24
7 1.35 ± 0.39 7.91 ± 1.28 37.00 ± 10.61 0.00 ± 0.00 36.00 ± 10.61
Table 2 Blood test values of uninfected mice treated with the decoction of Cocos nucifera leaves at day 1, day 8, and day 16 post treatment.
Normal values are placed below each parameter title
Parameter Day 1
2000 1000 750
Control Treated Control Treated Control Treated
Hematocrit (%) 31.9 ± 1.22 35.32 ± 2.25 31.5 ± 1.70 34.54 ± 2.62 28.57 ± 6.54 28.76 ± 3.37
33–48%
Hemoglobin (g/dL) 9.73 ± 1.7 11.66 ± 0.86 10.3 ± 0.35 11.5 ± 0.86 9.47 ± 2.16 9.58 ± 1.16
10–16
MCV (fl/red cell) 50.23 ± 2.03 48.26 ± 2.3 48.33 ± 2.5 48.72 ± 1.33 50.23 ± 2.03 52.24 ± 2.94
42.3–55.2
Parameter Day 8
2000 1000 750
Control Treated Control Treated Control Treated
Hematocrit (%) 32.2 ± 0.35 17.75 ± 15.54 26.4 ± 5.86 28.54 ± 4.99 23.33 ± 0.58 20.74 ± 8.88
33–48%
Hemoglobin (g/dL) 10.67 ± 0.12 5.90 ± 5.16 8.77 ± 1.98 9.48 ± 1.69 7.73 ± 0.23 6.88 ± 2.96
10–16
MCV (fl/red cell) 51.10 ± 0.40 61.15 ± 13.61 47.7 ± 3.42 50.24 ± 3.70 50.63 ± 1.70 51.52 ± 1.5
42.3–55.2
Parameter Day 16
2000 1000 750
Control Treated Control Treated Control Treated
Hematocrit (%) 32.7 ± 0.85 33.25 ± 2.47 26.4 ± 5.86 28.54 ± 4.99 32.2 ± 0.35 21.96 ± 5.03
33–48%
Hemoglobin (g/dL) 9.85 ± 1.34 11.05 ± 0.78 8.77 ± 1.98 9.48 ± 1.69 10.67 ± 0.12 7.28 ± 1.68
10–16
MCV (fl/red cell) 50 ± 1.84 53.2 ± 1.84 47.7 ± 3.42 50.24 ± 3.7 51.1 ± 0.4 39.10 ± 12.2
42.3–55.2
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Prophylactic test
At the end of treatment, the parasitemia percentage in
infected mice treated with 500 and 750 mg/kg/day was
30.16 ± 5.03 and 23.28 ± 12.89, respectively (Fig. 4).
The untreated group had a percentage parasitemia of
42.25 ± 7.89, whereas that of the chloroquine-treated
control was 6.95 ± 1.84. The percentage chemosuppres-
sion of parasites in mice treated with 500 and 750 mg/
kg/day was 28.60% and 44.91%, whereas that of the
treatment with chloroquine was 83.56%.
Discussion
We carried out experiments to test the antimalarial activity
of the extract from the leaves of C. nucifera on mice
infected with P. berghei parasites, examining the routes of
administration, the acute toxicity and different assays to
determine its antiplasmodial effects.
The IM-treated mice were less susceptible to weight loss
when compared with the other two routes of administra-
tion, oral and subcutaneous. Additionally, there was a
greater antiplasmodial effect in these animals when com-
pared to those treated subcutaneously and intragastrically.
The latter administration of the extract involves the drug
being subjected to the stomach acids which may cause it to
be degraded (Levine 1970). Besides, using a gavage
administration probably affected the animals’ ability to eat
properly, resulting in weight loss, while subcutaneous
administration may hinder the extract from reaching cir-
culation and may not act against the parasites since the rate
of absorption in this route is lower than intramuscular
administration (Simmons and Brick 1970).
Our results for the acute toxicity assay showed that the
extract presented signs of toxicity at the maximum con-
centration used (2000 mg/kg/day) when administered
intramuscularly. In the group treated with the extract, two
of the five mice died, with deaths beginning on the 6th day,
suggesting that the dose at which half of the population
dies (LD50) lies slightly beyond 2000 mg/kg/day, since no
animals died at 1000 mg/kg/day. Blood analysis of hema-
tocrit and hemoglobin levels in all groups remained gen-
erally within the normal values up until day 8, when the
three concentrations used apparently caused the hemoglo-
bin to fall below the lower normal limit. This trend con-
tinued until day 16th suggesting that the extract negatively
affects the integrity of red blood cells if used for periods
longer than 8 days. Further experiments should monitor
these levels more closely to determine the effects on
hematocrit and hemoglobin parameters of the mice on a
daily basis. Additionally, mean cell volume (MCV)
parameters were analyzed in all groups. MCV is a measure
Fig. 2 Treatment of infected mice with 500 and 750 mg/kg/day of
the extract. Results shown are the mean of 5 mice in each group.
Parasite growth was determined by microscopy and compared to
controls with only vehicle added. Results shown are the mean of 5
mice ± SEM values. A p B 0.05 was considered significant.
a = p\0.05, b = p\0.01, c = p\0.005, d = p\0.0001
Fig. 3 Curative assay of C. nucifera extract against P. berghei.
Results shown are the mean of five mice ± SEM values. Parasite
growth was determined by microscopy and compared to culture
controls with only vehicle added. Day 1 [D1] is the 1 day of treatment
after 72 h of untreated parasite infection
Fig. 4 Prophylactic assay of C. nucifera extracts against P. berghei.
Parasite growth was determined by flow cytometry and compared to
culture controls with only vehicle added. Results shown are the mean
of 5 mice ± SEM values
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of the size of red blood cells and low values (normal ref-
erence range is typically 42.3–55.2 fl/red cell) are indica-
tive of microcytic anemia (Dasgupta 2015).This parameter
was found to be normal after inoculating the extract in all
treated groups, indicating that, while the extract affects
hemoglobin and hematocrit levels after the first 8 days, the
size of the RBCs remains unaffected for extended periods
of treatment.
At concentrations of 500 and 750 mg/kg/day, the leaf
extract was able to exert a parasite chemosuppression of
51% and 54%, respectively. The slightly higher activity
achieved at 750 mg/kg/day suggests that this extract has a
moderate suppressive activity (Deharo et al. 2001). Tests
using concentrations between 750 and 1000 mg/kg/day
should be explored to improve chemosuppression, but
avoiding the slight toxicity found in the mice at 1000 mg/
kg/day.
The extract does not show any curative effect when
tested at concentrations of 500 and 750 mg/kg/day on P.
berghei—infected mice. Nonetheless, in the prophylactic
test, the extract at 500 and 750 mg/kg/day showed a dose-
dependent activity against the parasite with P. falciparum
inhibitory percentages of 28.60% and 44.91%, respec-
tively. For a comparison with a classic anti-malarial drug,
the use of chloroquine before infection was 83.56% effi-
cient in stopping the infection.
Different products from the coconut plant have been
studied extensively for their medicinal properties (Roopan
2016). Research has demonstrated the presence of
metabolites such as polyphenols, glycosides, steroids,
alkaloids, terpenoids, and others which could be responsi-
ble for those activities (Renjith et al. 2013; Manalo et al.
2017; Oliveira et al. 2009; Singla et al. 2011; Soumya et al.
2014). More specifically, the husk extracts of C. nucifera
have shown to have antimalarial properties when tested
in vitro and in vivo (Adebayo et al. 2012; Adebayo et al.
2013; Balogun et al. 2014; Angeles et al. 2005).
Previous research by our group (Tayler et al. 2019)
demonstrated the presence of flavan-3-ols (epicatechin),
flavones (catechin derivatives, isoorientin, apigenin,
vitexin, isovitexin, and luteolin) in the leaves of C. nucifera
from Punta Patin˜o, Panama, and the in vitro antiplasmodial
activity of a water decoction of these leaves was described.
Flavonoids are phenolic compounds and one of the most
common secondary metabolites found in plants. Flavonoids
such as acacetin, apigenin, baicalein, chrysin, genistein,
kaempferol, luteolin, among many others have been iden-
tified to possess antimalarial activity (Lehane and Saliba
2008). Additionally, compounds from the catechin family
have been involved in antimalarial action (Sannella et al.
2007).
Fatty acid synthesis is of utmost importance in the
development of malarial parasites. They are needed for
parasite membrane and lipid body biogenesis (Palacpac
et al. 2004) and they are used for the anchorage of parasite
membrane proteins through glycosylphosphatidylinositol
moieties (Gilson et al. 2006). There are three important
enzymes involved in the fatty acid biosynthesis of P. fal-
ciparum, namely 3-hydroxyacyl-[acyl-carrier-protein]
dehydratase (FabZ), 3-oxoacyl-[acyl-carrier-protein]
reductase (FabG), and Enoyl-[acyl-carrier-protein] reduc-
tase [NADH] (FabI) (Tasdemir et al. 2006). In a study from
Tasdemir et al. (2006) it was demonstrated that the flavo-
noids belonging to the gallic acid esters of catechins were
the most active compounds against the parasite. They per-
formed kinetic analyses using luteolin and (-)-catechin
gallate as model compounds and revealed that FabZ was
inhibited competitively. FabG was inhibited in a noncom-
petitive manner, whereas both compounds behaved as tight-
binding noncompetitive inhibitors of FabI. Additionally,
these polyphenols showed in vitro activity against chloro-
quine-sensitive (NF54) and -resistant (K1) P. falciparum
strains in the low to submicromolar range (Tasdemir et al.
2006). Furthermore, in the presence of catechins from green
tea and other important plant polyphenols, the inhibitory
effect of triclosan binding to FabI from P. falciparum was
potentiated (Sharma et al. 2007). The heightened binding of
triclosan because of the high affinity of catechins was fur-
thermore explained by molecular modeling studies based on
flavonoids luteolin, quercetin, fistein, (-)-catechin gallate,
and others (Banerjee et al. 2008). Modelling also correlated
with the activity of luteolin against chloroquine-sensitive
and chloroquine-resistant strains of P. falciparum, follow-
ing in silico studies where it was shown that luteolin had
good binding affinity against dihydrooroate dehydrogenase
(PfDHODH) and plasma membrane P-type cation translo-
cating ATPase (PfATP4), two enzymes needed for the
survival of the parasite. In vitro testing confirmed the
finding showing low micromolar activity againt P. falci-
parum. The flavonoids were found in the juice of Citrus
species used traditionally for the treatment of malaria-as-
sociated fevers (Gogoi et al. 2019).
Several studies describe how catechin-related com-
pounds such as epigallocatechin-3-gallate (EGCG) and
epicatechin gallate (ECG) show moderate antiplasmodial
effects. In a study by Sannella et al. (2007), a crude extract,
as well as EGCG and ECG from green tea leaves, were
found to strongly inhibit the growth of P. falciparum par-
asites in vitro. Additionally, they found that these catechins
were able to potentiate the effect of artemisinin when used
in combination against malaria parasites (Sannella et al.
2007).
The presence of flavan-3-ols (epicatechin), flavones
(catechin derivatives, isoorientin and luteolin, among many
others) could help explain the parasitemia reduction of P.
berghei-infected mice tested in this study. It is clear, from
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the chemosupression percentages of 51% and 54% in a
4-day suppressive assay, in addition to a moderate pro-
phylactic actity, that our crude extract from C. nucifera
possesses antimalarial properties. Acute toxicity assays,
however, showed a slight harming effect of this extract on
hematocrit and hemoglobin parameters for the group which
showed 54% chemosuppression. Even with this finding, the
extract from C. nucifera leaves is a candidate for further
analysis using a bioassay-guided isolation of compounds
and/or fractions selected from the whole decoction. In
addition, it would be valuable to determine the combina-
torial effect this extract, and/or its compounds, could have
on malaria parasites when paired with standard drugs.
These approaches could result in new candidates and/or
structures for drug development against human malaria.
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